Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QPexin
- Development stage
- Unknown
- Lead developer
- Shionogi
01
Overview
QPexin is a clinical-stage antibiotic that was originally developed by QPeX Biopharma and subsequently acquired by Shionogi. It is currently in Phase 3 development for the treatment of multidrug-resistant Gram-negative infections, addressing the critical need for new treatments against antimicrobial resistance (AMR).
Beyond the preview
Go deeper on QPexin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QPexin.